8 results about "Single administration" patented technology

The present invention relates to a composition comprising sialyloligosaccharide and N-acetylmannosamine for the treatment of GNE myopathy, and a method of using same. Despite ManNac exhibiting non-significant sialylation activity in GNE knockdown (GNE KD) C2C12 skeletal muscle cells, it was confirmed that co-administration of ManNac and sialyloligosaccharide promotes sialylation more effectively than single administration, thereby exhibiting an excellent synergistic effect. Such effects have also been confirmed in an animal model of GNE myopathy, and thus the combined therapy of ManNAc and sialyloligosaccharide of the present invention is expected to be advantageously employed as a novel therapeutic approach capable of overcoming hyposialylation caused by sialic acid deficiency in GNE myopathy.

The present application belongs to the technical field of medicine, and relates to a kind of pharmaceutical composition and its application in preparation for treating or preventing liver fibrosis drug. A kind of pharmaceutical composition for treating or preventing liver fibrosis, the pharmaceutical composition includes as active ingredient the protocatechuic acid (PCA) and gimalin (GER). The present application first confirms that protocatechuic acid and gimalin combined application has significant synergistic effect in the treatment of liver fibrosis, and its curative effect is better than any single compound single administration, can more effectively reduce liver injury index, improve liver pathological morphology, reduce intrahepatic collagen deposition. Based on its clear mechanism of action, the composition of the present application is especially suitable for treating liver fibrosis related to abnormal expression of RIPK3.

In one aspect, the present disclosure provides a platform accessory for an angled subcutaneous injection and for delivering a medicament comprising a hyaluronidase. In another aspect, the present disclosure provides a method of administering a high volume formulation in a single administration to treat a disease or condition in a subject via a platform accessory for an angled subcutaneous injection.

In one aspect, the present description provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present description provides a method for administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.

The present application provides a kind of targeting folate receptor antibody conjugated drug in colorectal cancer and its humanization.The specific application provides the application of the drug conjugate of anti-FOLR1 antibody and VcMMAE conjugation in the treatment of colorectal cancer.In addition, the present application also provides the application of the combination of the drug conjugate and gemcitabine in the treatment of colorectal cancer, and the combination of the drug conjugate and gemcitabine has better inhibitory effect on colorectal cancer than single administration.

In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.

The application discloses a Chinese-western medicine pharmaceutical composition containing Liuwei Dihuang extract and application thereof in preparation of a medicine for treating liver cancer. The pharmaceutical composition comprises leflunomide and Liuwei Dihuang extract, and the Liuwei Dihuang extract is Liuwei Dihuang pill water extract or Liuwei Dihuang pill alcohol extract. In the pharmaceutical composition, the leflunomide and the Liuwei Dihuang extract can be mixed together to form a single administration unit, or can be independent administration units and used respectively. The application compares the administration of leflunomide alone, leflunomide combined with Liuwei Dihuang water extract, leflunomide combined with Liuwei Dihuang alcohol extract, Liuwei Dihuang water extract alone and Liuwei Dihuang alcohol extract alone. The results of animal experiments and cell experiments show that the Liuwei Dihuang alcohol extract has a significant effect of promoting the treatment of liver cancer by leflunomide. The application can be converted to clinic, and provides a possibility of reducing the dosage of leflunomide for clinical medication, which is helpful for the treatment of liver cancer.

The application discloses a low-stimulus and high-safety benzoyl aconine original base temperature-sensitive analgesic gel injection as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The injection takes benzoyl aconine original base as a core analgesic component, constructs a triple heart protection system of'sub-anesthetic dose lidocaine + ammonium glycyrrhizinate + magnesium sulfate', cooperates with a poloxamer 407 temperature-sensitive gel matrix, and is supplemented with a cosolvent and an antioxidant, has a pH value of 5.5-6.5, can be injected at room temperature, and is quickly gelled at body temperature to realize long-acting controlled release. The preparation has high analgesic intensity, no addiction, slight injection pain, controllable cardiotoxicity, and can maintain analgesia for more than 12 hours after single administration, is suitable for local targeted treatment of moderate and severe chronic pain, neuropathic pain and the like, and has significant clinical advantages and popularization value.